Monsonet M, Rockwood NJ, Kwapil TR, Barrantes-Vidal N. Psychological pathways to paranoia and psychotic-like experiences in daily-life: the mediating role of distinct affective disturbances. Schizophr Bull. 2022 Sep 1;48(5):1053-65. doi: 10.1093/schbul/sbac071
Andrews S, Mansfield C, O'Neill C, Peay H. Meaningful treatment outcomes for Sanfilippo syndrome: using a combination of focus groups and best-worst scaling to elicit and explore parents' priorities. Poster presented at the 2019 25th Annual Qualitative Health Research Conference; October 2019. Vancouver, Canada. [abstract] Int J Qual Methods. 2020 Mar 30; 19:2. doi: 10.1177/1609406920909934
Galinksy J, Richard S, Morris M. Myeloma patients' self-reported experiences of care and treatment. Cancer Nurs Pract. 2016 Sep 14;15(7):22-6. doi: 10.7748/cnp.2016.e1341
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.